Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company that completed its business combination with Lakeshore Acquisition II Corp., a blank-check company sponsored by Lakeshore Acquisition II Sponsor LLC, in 2024. Lakeshore Acquisition II conducted its initial public offering in 2022, targeting the healthcare and life sciences sector. Abpro focuses on the discovery and development of bispecific antibody-based therapeutics for oncology and other serious diseases. The combined company trades on Nasdaq under the ticker ABP following the close of the de-SPAC transaction. The company submitted an 8-K current report to the SEC on November 26, 2024. Sign up for full data on SpacDesk to access complete filings, deal analytics, and real-time SPAC intelligence on ABP and hundreds of other transactions.